Integral Diagnostics Ltd (ASX: IDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Integral Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Integral Diagnostics Ltd (ASX: IDX)
Latest News
⏸️ Investing
Why WAM Microcap Limited owns shares of this company
⏸️ Investing
These 3 shares had a brilliant 2018
⏸️ Investing
Capitol Health Ltd lobs takeover bid for Integral Diagnostics Ltd
⏸️ Investing
Why the Big Un Ltd share price shot up 20%
⏸️ Investing
5 shares you need to watch on Wednesday
⏸️ Investing
The 10 least short-sold shares on the ASX
⏸️ Investing
Top broker names 11 small caps to buy now
⏸️ Investing
Why these 3 ASX shares just hit 52-week lows
⏸️ Investing
These 6 stocks have dropped more than 18% in the past week
⏸️ Investing
4 shares sinking on the ASX today
⏸️ Investing
Sonic Healthcare Limited looks good with German expansion
⏸️ Investing
Should you buy these 4 health care stocks?
Frequently Asked Questions
-
Yes, Integral Diagnostics historically pays two fully franked dividends a year.
-
Integral Diagnostics generally pays its shareholder dividends in April and October.
-
Integral Diagnostics Ltd listed on the ASX on 21 October 2015.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
30 Aug 2024 | $0.0330 | 100.00% | Final | 03 Oct 2024 |
29 Feb 2024 | $0.0250 | 100.00% | Interim | 02 Apr 2024 |
31 Aug 2023 | $0.0350 | 100.00% | Final | 04 Oct 2023 |
02 Mar 2023 | $0.0250 | 100.00% | Interim | 04 Apr 2023 |
01 Sep 2022 | $0.0300 | 100.00% | Final | 05 Oct 2022 |
01 Mar 2022 | $0.0400 | 100.00% | Interim | 04 Apr 2022 |
02 Sep 2021 | $0.0700 | 100.00% | Final | 06 Oct 2021 |
01 Mar 2021 | $0.0550 | 100.00% | Interim | 06 Apr 2021 |
28 Aug 2020 | $0.0400 | 100.00% | Final | 01 Oct 2020 |
28 Feb 2020 | $0.0550 | 100.00% | Interim | 07 Apr 2020 |
30 Aug 2019 | $0.0500 | 100.00% | Final | 02 Oct 2019 |
01 Mar 2019 | $0.0500 | 100.00% | Interim | 02 Apr 2019 |
31 Aug 2018 | $0.0400 | 100.00% | Final | 04 Oct 2018 |
31 Jan 2018 | $0.0400 | 100.00% | Interim | 05 Mar 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 04 Oct 2017 |
28 Feb 2017 | $0.0300 | 100.00% | Interim | 30 Mar 2017 |
31 Aug 2016 | $0.0400 | 100.00% | Final | 04 Oct 2016 |
IDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Integral Diagnostics Ltd
Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services.
The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients.
The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.
IDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Nov 2024 | $3.06 | $0.00 | 0.00% | 4,786,879 | $3.09 | $3.10 | $3.05 |
07 Nov 2024 | $3.06 | $0.06 | 2.00% | 182,227 | $3.03 | $3.08 | $3.02 |
06 Nov 2024 | $3.00 | $0.05 | 1.69% | 740,155 | $2.96 | $3.03 | $2.94 |
05 Nov 2024 | $2.95 | $-0.04 | -1.34% | 369,410 | $2.98 | $2.99 | $2.95 |
04 Nov 2024 | $2.99 | $0.00 | 0.00% | 250,366 | $2.99 | $3.01 | $2.94 |
01 Nov 2024 | $2.99 | $-0.14 | -4.47% | 910,422 | $3.14 | $3.14 | $2.96 |
31 Oct 2024 | $3.13 | $0.03 | 0.97% | 338,797 | $3.10 | $3.17 | $3.10 |
30 Oct 2024 | $3.10 | $0.00 | 0.00% | 284,233 | $3.10 | $3.12 | $3.08 |
29 Oct 2024 | $3.10 | $-0.02 | -0.64% | 833,015 | $3.11 | $3.17 | $3.10 |
28 Oct 2024 | $3.12 | $-0.04 | -1.27% | 459,137 | $3.17 | $3.17 | $3.11 |
25 Oct 2024 | $3.16 | $0.03 | 0.96% | 421,424 | $3.13 | $3.19 | $3.13 |
24 Oct 2024 | $3.13 | $0.02 | 0.64% | 381,300 | $3.10 | $3.17 | $3.06 |
23 Oct 2024 | $3.11 | $-0.06 | -1.89% | 448,678 | $3.18 | $3.20 | $3.10 |
22 Oct 2024 | $3.17 | $0.09 | 2.92% | 640,927 | $3.08 | $3.17 | $3.07 |
21 Oct 2024 | $3.08 | $-0.01 | -0.32% | 465,138 | $3.12 | $3.15 | $3.08 |
18 Oct 2024 | $3.09 | $-0.04 | -1.28% | 396,113 | $3.13 | $3.14 | $3.07 |
17 Oct 2024 | $3.13 | $0.04 | 1.29% | 1,093,274 | $3.10 | $3.13 | $3.06 |
16 Oct 2024 | $3.09 | $0.04 | 1.31% | 616,547 | $3.03 | $3.11 | $3.03 |
15 Oct 2024 | $3.05 | $-0.02 | -0.65% | 409,808 | $3.07 | $3.08 | $3.03 |
14 Oct 2024 | $3.07 | $-0.01 | -0.32% | 346,491 | $3.12 | $3.12 | $3.07 |
11 Oct 2024 | $3.08 | $-0.01 | -0.32% | 1,968,871 | $3.12 | $3.12 | $3.05 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
01 Nov 2024 | Ian Kadish | Issued | 327,566 | $979,422 |
Issue of securities. 1,004,570 Rights
|
16 Sep 2024 | Ian Kadish | Issued | 29,072 | $74,424 |
Issue of securities. 677,004 Rights
|
30 Aug 2024 | Ian Kadish | Issued | 26,035 | $67,691 |
Conversion of securities.
|
30 Aug 2024 | Ian Kadish | Exercise | 26,035 | $67,691 |
Conversion of securities. 647,932 Rights,
|
27 Aug 2024 | Ian Kadish | Expiry | 184,616 | $480,001 |
As advised by the company. Lapsed, 673,967 Rights
|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP).
|
01 Dec 2023 | Andrew Fay | Buy | 15,000 | $25,575 |
On-market trade.
|
01 Dec 2023 | Ian Kadish | Buy | 20,000 | $35,050 |
On-market trade.
|
30 Nov 2023 | Ingrid Player | Buy | 35,000 | $60,725 |
On-market trade.
|
30 Nov 2023 | James Hall | Buy | 150,000 | $258,225 |
On-market trade.
|
30 Nov 2023 | Ian Kadish | Issued | 248,970 | $441,921 |
Issue of securities. 858,583 - Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Andrew James Fay | Non-Executive Director | Jul 2022 |
Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. He is also Chair of the People and Culture Committee.
|
Ms Raelene Margaret Murphy | Non-Executive Director | Oct 2017 |
Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Ms Ingrid Anne Player | Non-Executive Director | Aug 2023 |
Ms Player has more than 20 years of experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australia's largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specializing in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She is Chair of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Mr James Tobias Hall | Non-Executive Director | Sep 2023 |
Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra and advisory board member for Fujitsu Australia and New Zealand. He is a Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Dr Ian Kadish | Chief Executive OfficerManaging Director | May 2017 |
Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee. He is a Member of the Integral Clinical Leadership Committee.
|
Mr John J Merity | Interim Company Secretary | Jun 2024 |
-
|
Ms Nikki Dalla Valle | Company Secretary | Dec 2023 |
-
|
Craig White | Chief Financial Officer |
-
|
|
Nikki Dalla Valle | Company Secretary |
-
|
|
John J Merity | Interim Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Limited | 42,793,666 | 18.29% |
J P Morgan Nominees Australia Pty Limited | 39,158,798 | 16.74% |
HSBC Custody Nominees (Australia) Limited | 38,626,662 | 16.51% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 4,678,603 | 2.00% |
Warbont Nominees Pty Ltd (Unpaid Entrepot A/c) | 4,119,561 | 1.76% |
Washington H Soul Pattinson And Company Limited | 4,087,223 | 1.75% |
HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) | 3,906,185 | 1.67% |
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) | 3,552,881 | 1.52% |
BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) | 3,407,901 | 1.46% |
New Imaging Pty Ltd (New Imaging A/c) | 3,389,045 | 1.45% |
Lethean Holdings Pty Ltd (Howitt No 8 A/c) | 2,944,760 | 1.26% |
Firbar Pty Ltd (The Howitt No 4 A/c) | 2,357,230 | 1.01% |
J A Mullins Pty Ltd (James A Mullins Family A/c) | 2,316,051 | 0.99% |
Masfen Securities Limited | 2,250,000 | 0.96% |
Mittal Holdings Pty Ltd (Howitt No 12 A/c) | 2,085,907 | 0.89% |
Mr Vincent Michael O'Sullivan (O'Sullivan A/c) | 2,020,000 | 0.86% |
Wyndham Salter Pty Ltd (The Howitt No 10 A/c) | 1,792,947 | 0.77% |
A & S French Pty Ltd (The AJ French Family A/c) | 1,778,327 | 0.76% |
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 1,711,682 | 0.72% |
BNP Paribas Noms Pty Ltd | 1,636,566 | 0.70% |